Mitragynine is the primary active compound in kratom, a tropical tree native to Southeast Asia. It makes up the largest share of the plant’s alkaloid content, typically ranging from 0.75% to 2.66% of dried leaf weight, and is responsible for most of kratom’s pain-relieving and mood-altering effects. Chemically classified as an indole alkaloid, mitragynine interacts with the same brain receptors targeted by opioid drugs, though it behaves quite differently from conventional opioids in several important ways.
Where Mitragynine Comes From
Mitragynine occurs naturally in the leaves of Mitragyna speciosa, commonly known as kratom. The concentration varies significantly depending on the plant’s growing conditions, genetics, and leaf maturity. A large survey of wild kratom trees in Thailand found mitragynine content ranging from 7.5 to 26.6 milligrams per gram of dried leaf, with an average around 16 mg/g. That wide range means two batches of kratom leaf can deliver very different amounts of mitragynine even at the same weight.
Kratom leaves contain dozens of alkaloids, but mitragynine is by far the most abundant. A much smaller fraction converts into a related compound called 7-hydroxymitragynine, which is far more potent and has become the focus of separate regulatory action.
How It Works in the Body
Mitragynine acts as a partial agonist at the mu-opioid receptor, the same receptor activated by morphine, codeine, and fentanyl. “Partial agonist” means it activates that receptor less fully than those drugs do. In animal studies, mitragynine was roughly 2.6 times weaker than codeine at reducing pain responses, and codeine itself is already considered a mild opioid. In rat studies, mitragynine often failed to produce measurable pain relief at all in standard tests, while morphine and fentanyl reliably did.
This partial activation has a significant practical consequence: mitragynine appears to produce little to no respiratory depression, even at doses many times higher than what people typically consume. Respiratory depression (dangerously slowed breathing) is the mechanism behind most opioid overdose deaths. Researchers attribute this safety margin to the fact that mitragynine activates the opioid receptor through a slightly different signaling pathway, one that doesn’t strongly recruit the cellular machinery responsible for suppressing breathing.
Kratom’s effects also shift depending on how much someone takes. At lower doses, it tends to produce stimulant-like effects: increased energy, alertness, and sociability. At higher doses, the opioid-like qualities become more prominent, producing sedation, relaxation, and pain relief. This dual nature is unusual and partly explains why kratom doesn’t fit neatly into existing drug categories.
How the Liver Processes Mitragynine
Once ingested, mitragynine is broken down by several liver enzymes. Four specific enzymes in the CYP450 family handle most of the work: CYP2C18, CYP2C19, CYP2D6, and CYP3A4. Each produces different metabolites. The most abundant breakdown product found in urine is called 9-O-demethylmitragynine, generated primarily by CYP2C19, CYP3A4, and CYP2D6.
One metabolic pathway stands out as especially important. CYP3A4, exclusively, converts a small amount of mitragynine into 7-hydroxymitragynine, a compound with more than 10 times the binding affinity for the mu-opioid receptor compared to morphine. This means your body actually creates a more potent opioid-like substance from mitragynine during normal metabolism. The amount produced is small, but it likely contributes to kratom’s overall pain-relieving effects.
Drug Interaction Risks
The liver enzymes that process mitragynine, particularly CYP3A4 and CYP2D6, also metabolize over half of all prescription medications. Mitragynine can inhibit these enzymes, meaning other drugs that rely on the same pathways can build up to higher (and potentially dangerous) levels in the bloodstream.
Several case reports illustrate the danger. In one case, a 27-year-old man experienced toxic effects after combining kratom with the antipsychotic quetiapine, which depends heavily on CYP3A4 for elimination. In another, a 36-year-old man developed serotonin syndrome and heart rhythm abnormalities after taking an extremely high dose of kratom (around 90 grams per day) alongside the antidepressant venlafaxine and quetiapine. The suspected mechanism in both cases was mitragynine blocking the breakdown of those prescription drugs.
Overdose deaths involving kratom alkaloids almost always involve other substances. Opioids, benzodiazepines, and stimulants are the most commonly co-detected drugs. The pharmacokinetic interaction, where mitragynine slows the elimination of another drug, can turn a normally safe dose of a prescription medication into a toxic one. Combining kratom with any centrally acting drug, especially opioids, sedatives, or antidepressants, carries real risk.
Side Effects and Safety Profile
The most common side effects reported by regular kratom users are nausea, indigestion, constipation, dizziness, and occasionally heart palpitations. These tend to be mild, self-resolving, and often serve as a natural limit on intake since higher doses cause more stomach discomfort.
No lethal dose of mitragynine has been established in humans. In controlled studies, mitragynine produced sedative effects milder than those caused by oxycodone at the highest tested doses, with no significant respiratory depression. Blood concentrations in postmortem cases have been measured as high as 11,000 ng/mL, but researchers caution there isn’t enough data to define a threshold concentration that’s reliably fatal. Concentrations above 1,000 ng/mL appear more likely to be associated with severe outcomes, though co-ingested substances are nearly always present in serious cases.
The most dangerous scenarios involve contaminated or adulterated products. Kratom products have been found to contain undisclosed additives including fentanyl, methamphetamine, and bacterial contaminants like salmonella. These adulterants, not mitragynine itself, account for many of the most serious harms attributed to kratom.
Current Legal and Regulatory Status
Mitragynine is not a federally scheduled substance in the United States. However, several states and municipalities have banned or regulated kratom independently. The FDA has not approved any kratom-derived products for medical use.
Regulatory attention has recently shifted toward 7-hydroxymitragynine, the more potent metabolite. The FDA recommended that the DEA schedule concentrated 7-hydroxymitragynine products under the Controlled Substances Act, specifically targeting manufactured 7-OH tablets, gummies, drink mixes, and shots. The agency emphasized it is not focused on natural kratom leaf products with this action. The DEA is reviewing the recommendation and would need to complete a rulemaking process, including a public comment period, before any scheduling takes effect.
This regulatory distinction between natural kratom leaf (where mitragynine dominates) and concentrated 7-OH products reflects the significant potency difference between the two compounds and the higher risk profile associated with isolated 7-hydroxymitragynine.